It's elementary my dear Watson, you are only hurting the stock with your incessant "technospeak". Keep it up to driving it back down to $.03.
Folks, cash is running out for them-going to need a dilutive stock issuance to stay afloat. They have already maxed out on all other funding options. And unfortunately they are obligated to pay off past due vendors first before using any of the proceeds for future beneficial purposes. They will not be able to get enough funding to stay around for the next 2-3 years they need to get to sales phase. IP is only valued at $600K for anyone to buy them.
Ask yourself why you are investing in AMBS?
a.) It was a pump and dump on penny stock alerts this week
b.) Speculative play of a BD buyout/deal
c.) cheap play in biotech that is a hit or miss
d.) bought in to the hype in January at $.15 so hanging on to the end
a.) late to the party-missed it on Monday/Tuesday but maybe it will cycle through the rotation again
b.) BD has no interest to get exclusivity but hey live the fantasy. They can wait for B/K to get it.
c.) OK but don't risk anything more than you are willing to throw out the window (at least someone could catch it and use it for something good)
d.) so sorry for you
Mine is new because someone hacked my old one: suckittome
as if you have been around very long...
472 posts | Last Activity: 1 minute 17 seconds ago Member since: Jan 31, 2013
and yes most of my posts are negative because I am SNARKY! Ferreting out the BS that started appearing on decent MB's by posters with their penny stock junk. Love following the trail, crashing the party and with a little DD, sobering up the party guests. Don't want them to get caught drinkin' and tradin'.
I did type in AMBS in my browser once and it was listed with 4 other stocks on a stupid penny stock alert. So was INO. So was CPRX. So was NVIV... The list goes on and on. They just look for momentum. MANF has real science behind it just like GDNF. Look what happened to Synergen when Amgen bought them out for $260 million. I don't know which is better of the two, but from the science available right now (all preclinical) they look about the same.
So give AMBS a 260 million market cap based on precedence is fair. Now take in inflation from that buyout in 1993, how would that price out. 1% a year minimum inflation for 20 years. That's $300 million right there. Add in Lympro (hopefully) and we'll see what a 800 million market cap stock does to a stock that is trading less than 7 cents. Best to all.